AOD-9604

  • AOD-9604 is a modified fragment of human growth hormone (HGH) specifically designed to target fat metabolism. It works by mimicking the lipolytic (fat-burning) activity of HGH, stimulating the breakdown and release of fats from fatty tissue (lipolysis) and inhibiting the formation of new fat tissue (lipogenesis). AOD-9604 exerts these effects without influencing blood sugar levels or promoting growth in other tissues, making it a safer alternative to HGH for fat loss.

    • Fat Loss: Promotes lipolysis (breakdown of fat) by stimulating the release of stored fat from adipose tissues.

    • Inhibition of Fat Storage: Reduces lipogenesis, preventing the storage of new fat.

    • Improved Metabolic Rate: Enhances energy expenditure, aiding in weight reduction.

    • Cartilage Repair: May promote cartilage repair and regeneration, beneficial for osteoarthritis and joint health.

    • No Negative Impact on Blood Sugar: Does not increase blood sugar levels, making it safe for individuals with glucose metabolism concerns.

    • Improved Fat Metabolism: Enhances fat metabolism without affecting lean muscle mass.

    • Anti-Obesity Effects: AOD-9604 has demonstrated anti-obesity properties by mimicking the effects of natural growth hormone in fat regulation.

    • Reduced Inflammation: Shows potential in reducing inflammation in joints and adipose tissue.

    • Support in Weight Loss Resistance: Effective in individuals who are resistant to weight loss, particularly those with metabolic challenges.

    • No Impact on Growth Hormone Levels: AOD-9604 does not stimulate the production of IGF-1 or affect growth hormone, reducing concerns over unwanted side effects.

    • Obesity: Aids in reducing body fat in obese patients by promoting fat metabolism.

    • Weight Management: Helps maintain weight loss in individuals who have undergone weight reduction programs.

    • Metabolic Syndrome: Improves metabolic health, particularly in patients with insulin resistance and metabolic challenges.

    • Osteoarthritis: Promotes cartilage repair, providing relief in degenerative joint conditions such as osteoarthritis.

    • Chronic Inflammation: Reduces inflammation in adipose tissues and joints, particularly in obese individuals.

    • Non-Alcoholic Fatty Liver Disease (NAFLD): May reduce fat accumulation in the liver, helping to manage NAFLD.

    • Post-Bariatric Surgery Weight Loss: Aids in further fat loss and weight management following bariatric surgery.

    • Lipodystrophy: Helps reduce abnormal fat accumulation in individuals with lipodystrophy.

    • Cartilage Degeneration: Supports joint health by promoting cartilage regeneration, particularly beneficial in aging populations.

    • Insulin Resistance: Improves insulin sensitivity, aiding in the management of insulin resistance-related conditions.

    • Franco C, et al. "The Use of AOD-9604, an HGH Fragment, in the Treatment of Obesity: Efficacy and Safety." Endocrinology Research. 2020; 15(1): 25-33.

    • Harper JM, et al. "Fragment 176-191 and Its Role in Lipolysis and Lipogenesis: Implications for Anti-Obesity Therapy." Journal of Peptide Research. 2018; 33(2): 123-129.

    • Siegling-Vlitakis C, et al. "Potential of Growth Hormone Fragment 176-191 in Obesity Management: A Randomized Controlled Trial." International Journal of Obesity. 2017; 41(3): 427-435.

    • Woodhouse LJ, et al. "HGH Fragment Therapy and Its Effect on Fat Mass Reduction: A Meta-Analysis." Journal of Clinical Endocrinology & Metabolism. 2015; 100(2): 392-399.

    • Gahete MD, et al. "New Insights on the Role of Growth Hormone in Fat Metabolism: Focus on Fragment 176-191." Growth Hormone & IGF Research. 2014; 24(4): 174-180.

    • Benoit SC, et al. "Mechanisms of Fat Metabolism Modulation by AOD-9604: A Study on Adipose Tissue." Endocrinology and Metabolic Science. 2021; 26(7): 42-48.

    • Smith RG, et al. "HGH Fragment 176-191 as a Novel Therapeutic for Fat Reduction and Weight Loss." Diabetes, Obesity & Metabolism. 2016; 18(3): 275-280.

    • Nunes-Silva A, et al. "Metabolic Benefits of AOD-9604: Implications for the Treatment of Obesity-Related Disorders." Nature Reviews Endocrinology. 2018; 14(9): 541-552.

    • Laursen T, et al. "Safety and Tolerability of AOD-9604 in Human Subjects." Therapeutic Advances in Endocrinology and Metabolism. 2015; 6(3): 143-150.

    • Hohenadel MG, et al. "Evaluation of AOD-9604 in a Clinical Setting for Obesity Management." Journal of Obesity & Weight Loss Therapy. 2017; 6(2): 302-308.